Product hub: Rapid contamination testing for cell culture and cell-based samples
The Celsis Adapt™ unlocks advantages of utilising a single in-house RMM, achieving critical results necessary to ensure patient safety.
The need for rapid microbiological methods (RMMs) for quality control is not new. The pharmaceutical industry has made slow progress adopting them over the last decade, with a sharp spike in uptake within the last two years. To resolve new challenges caused by the COVID-19 pandemic, contend with supply chain issues and release therapies faster to patients, the industry turned toward RMMs as a solution. The industry paradigm has shifted from rapid methods being a “nice to have” option to a model in which they are critical, if not necessary, for continuous operation and the ability to release products safely.
Related content from this organisation
- Globally harmonised microbial identification services with Charles River Accugenix®
- Guide to Outsourcing
- Cell and gene therapy manufacturing services market to value $13.8 billion by 2026
- Pharmaceutical QC market to value $9,700mn by 2027
- Automating microbial methods for data integrity in the modern age